Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN)
| CAPS Rating |
|
|---|---|
| Open | $16.61 |
| Previous Close | $17.05 |
| Daily Range | $16.60 - $17.27 |
| 52-Week Range | $8.03 - $18.30 |
| Market Cap | $2.50B |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 3,319,379 |
| Average Daily Volume | 0 |
AMLN
VS S&P 500 (SPY)
How do you think AMLN will perform against the market?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
AMLN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
AMLN News and Commentary
- 5 of Last Week's Biggest Winners – The Motley Fool
- Novo Nordisk Posts Solid 4Q - Analyst Blog – NASDAQ
- The Zacks Analyst Blog Highlights: Alkermes plc, Elan, Johnson & Johnson, Amylin Pharmaceuticals and – NASDAQ
- Stocks Set to Pull Back as Greek Debt Drama Rages On – NASDAQ
- The Week's Top Stock Gainers – The Motley Fool
- The Fool Looks Ahead – The Motley Fool
- Revenues Skyrocket at Merged Alkermes - Analyst Blog – NASDAQ
- New Study for Alkermes' Vivitrol - Analyst Blog – NASDAQ
- Amylin Pharmaceuticals Shares Popped Again: What You Need to Know – The Motley Fool
- Zyprexa Pulls Down Lilly's 4Q Sales - Analyst Blog – NASDAQ
- Company News for January 31, 2012 - Corporate Summary – NASDAQ
- UPDATE: Lilly 4Q Net Drops 27% As Zyprexa Sales Drop 44% – SmartMoney
- FDA Approves Amylin Diabetes Drug – Blogs @ The Motley Fool
- An Approval. Finally. – The Motley Fool
- US Stocks Edge Lower As Europe's Debt Flashpoints Weigh – SmartMoney
- Amylin Shares Surged: What You Need to Know – The Motley Fool
- Third Time Lucky for Amylin's Bydureon - Analyst Blog – NASDAQ
- Amylin Shares Rise on Diabetes Drug Approval, Challenges Loom – Minyanville
- US Stock Futures Lower On Renewed Worries Over Greece – SmartMoney
- Amylin Pharmaceuticals Motto: Try, Try, and then Try Again – Blogs @ The Motley Fool
RSS Headlines
Fool UK
